The PD-1 and PD-L1 Inhibitor Market is estimated to be valued at USD 52.51 Bn in 2024 and exhibit a CAGR of 18.3% over the forecast period 2024 - 2031. The market growth is driven by factors such as rising incidence of cancer and increasing R&D investments from key players. Furthermore, patent expiration of blockbuster drugs is expected to offer lucrative opportunities.
Market Dynamics:
Rising investments in cancer immunotherapy research, especially in developing innovative PD-1 and PD-L1 inhibitors, has boosted the market growth. Pharmaceutical companies are focusing on combination therapies and niche indications to strengthen their position. This is encouraging new clinical trials as well as product approvals. Patent Expirations of major drugs results in availability of lower-cost biosimilar and interchangeable versions. For instance, Roche's blockbuster drug Avastin went off-patent in 2018 followed by Sanofi's Erbitux in 2022 and Genentech's Herceptin in 2023. This has encouraged launch of affordable biosimilar substitutes, thereby enhancing access. It is anticipated to positively influence the PD-1 and PD-L Inhibitor Market.
Increasing prevalence of cancer globally
Cancer is one of the leading causes of death worldwide. According to the World Health Organization (WHO), cancer is responsible for nearly 10 million deaths globally each year. The increasing incidence and prevalence of various cancer types such as lung cancer, breast cancer, colorectal cancer etc. is expected to drive the demand for effective treatment options such as PD-1 and PD-L1 inhibitors. These drug classes have shown promising results in treating various advanced and metastatic cancers.
Favorable clinical research results and regulatory approvals
Multiple clinical trials have demonstrated the efficacy and safety of PD-1 and PD-L1 inhibitors either as monotherapy or in combination with other drugs in treating cancer types like melanoma, lung cancer and renal cell carcinoma. Various drugs in these classes have received regulatory approvals from major authorities like US FDA and EMA based on positive clinical data. The growing clinical evidence is boosting the confidence of oncologists to incorporate these drugs in treatment regimens. This factor is anticipated to fuel the adoption and sales of PD-1 and PD-L1 inhibitors in the forecast period.
High cost of therapy
PD-1 and PD-L1 inhibitors carry a very high cost of therapy, sometimes exceeding $100,000 per patient annually. This has made these promising treatments inaccessible to many cancer patients globally, especially in low and middle-income countries where healthcare budgets are limited. The exorbitant cost can negatively impact the market potential to some extent.
Safety concerns
While PD-1 and PD-L1 inhibitors demonstrate a better tolerability profile compared to conventional chemotherapy, they are still capable of triggering immune-related toxicities. Adverse effects reported include pneumonitis, hepatitis, colitis, endocrinopathies, and others. Rare but severe toxic reactions may discourage their use, limiting market growth. Continued monitoring is required to minimize risks.
Combination therapy
Combining PD-1 or PD-L1 inhibitors with other treatment modalities such as chemotherapy, radiation therapy and targeted therapy has emerged as a promising strategy to enhance clinical outcomes. Ongoing research on various combination regimens may further validate their efficacy, leading to expanded adoption in new cancer segments over time. This presents lucrative opportunities for market growth over the forecasted period.
Pipeline drugs
A thriving pipeline of next-generation PD-1 and PD-L1 inhibiting drug candidates targeting new tumor antigens with the potential for improved efficacy and safety profiles could capture additional market share. These include agents with longer duration of action allowing less frequent dosing or developed for specific biomarker-defined patient subsets. Successful clinical translation of pipeline assets will create growth prospects.
Link: https://www.coherentmarketinsights.com/market-insight/pd-1-and-pdl-1-inhibitors-market-173
Key Development
- On February 07, 2024, Bristol Myers Squibb, a multinational pharmaceutical corporation, disclosed two regulatory approvals pertaining to neoadjuvant administration of Opdivo (nivolumab) combined with chemotherapy preceding surgical intervention, as well as adjuvant employment of Opdivo in the perioperative management of surgically removable stage IIA to IIIB non-small cell lung cancer (NSCLC).
- On January 25, 2024, LAVA Therapeutics N.V., a clinical-stage biotechnology enterprise, declared the initiation of a clinical trial collaboration and supply arrangement with Merck, a multinational pharmaceutical corporation. This collaboration aims to assess the efficacy of their anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in conjunction with LAVA-1207, a Gammabody specifically engineered to target the prostate-specific membrane antigen (PSMA).
- On January 12, 2024, Merck announced that the U.S. Food and Drug Administration (FDA) had granted approval for Merck's anti-PD-1 drug, KEYTRUDA, in conjunction with chemoradiotherapy (CRT), for the therapeutic management of FIGO (International Federation of Gynecology and Obstetrics) 2014 Stage III-IVA cervical cancer
- On January 08, 2024, Medison Pharma, a prominent global pharmaceutical enterprise, announced the execution of an exclusive multinational agreement with Regeneron Ireland DAC, a wholly owned subsidiary of Regeneron Pharmaceuticals, Inc., a renowned biotechnology corporation. This agreement pertains to the commercialization of Libtayo (cemiplimab), a fully human monoclonal antibody specifically targeting the immune checkpoint receptor PD-1 on T cells, within designated European markets and other global markets.
Key Players: Pfizer Inc., Novartis AG, AstraZeneca PLC, Gilead Sciences Inc., Amgen Inc., Sanofi AG, F. Hoffmann-La Roche AG, Merck & Co., Bristol-Myers Squibb Company, Regeneron Pharmaceuticals Inc., Merck & Co., GSK plc, Ono Pharmaceutical Co., Ltd., Eli Lilly and Company, and BeiGene LTD
